Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTJ384)

• Drug Name: 18-Methoxycoronaridine Drug Info
• Synonyms: 18-methoxycoronaridine; 308123-60-6; DTXSID40437331

Indication

Disease Entry	ICD 11	Status	REF
Drug abuse	6C4G.1Z	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 15479177
  CAS Number: CAS 308123-60-6
  TTD Drug ID: DMTJ384

Molecule-Related Drug Atlas

Drug(s) Targeting Neuronal acetylcholine receptor alpha-2/alpha-3 (CHRNA2/A3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AZD-9684	DMHA5ME	Thrombosis	DB61-GB90	Discontinued in Phase 2	[3]
SIB-1533A	DMR5FD9	Discovery agent	N.A.	Investigative	[4]
Ibogaine	DM3HJX7	Discovery agent	N.A.	Investigative	[1]

Drug(s) Affected By Potassium voltage-gated channel subfamily H member 2 (KCNH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metoclopramide	DMFA5MY	Nausea	MD90	Approved	[5]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[6]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[7]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[8]
Clarithromycin	DM4M1SG	Acute maxillary sinusitis		Approved	[8]
Disopyramide	DM5SYZP	Long QT syndrome	BC65.0	Approved	[9]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[10]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[11]
Dofetilide	DMPN1TW	Sinus rhythm disorder	BC9Y	Approved	[12]
Flecainide	DMSQDLE	Tachyarrhythmias	BC71	Approved	[8]

Drug(s) Affected By Sodium channel protein type 5 subunit alpha (SCN5A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Disopyramide	DM5SYZP	Long QT syndrome	BC65.0	Approved	[13]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[14]
Flecainide	DMSQDLE	Tachyarrhythmias	BC71	Approved	[15]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[16]
Meloxicam	DM2AR7L	Arthritis	FA20	Approved	[17]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[18]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[19]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[20]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[21]
Retigabine	DMGNYIH	Behcet disease	4A62	Approved	[22]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Neuronal acetylcholine receptor alpha-2/alpha-3 (CHRNA2/A3)	TTMT0HG	ACHA2_HUMAN; ACHA3_HUMAN	Antagonist	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Gene/Protein Processing	[2]
Sodium channel protein type 5 subunit alpha (SCN5A)	OTGYZWR6	SCN5A_HUMAN	Gene/Protein Processing	[2]

References

• [1] Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration. Eur J Pharmacol. 2002 Mar 1;438(1-2):99-105.
• [2] Anti-addiction drug ibogaine inhibits voltage-gated ionic currents: a study to assess the drug's cardiac ion channel profile. Toxicol Appl Pharmacol. 2013 Dec 1;273(2):259-68. doi: 10.1016/j.taap.2013.05.012. Epub 2013 May 22.
• [3] Blockade and activation of the human neuronal nicotinic acetylcholine receptors by atracurium and laudanosine. Anesthesiology. 2001 Apr;94(4):643-51.
• [4] Nicotine, brain nicotinic receptors, and neuropsychiatric disorders. Arch Med Res. 2000 Mar-Apr;31(2):131-44.
• [5] Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology. 2005 Apr;74(1):31-6. doi: 10.1159/000083234. Epub 2005 Jan 7.
• [6] Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005 Jan;16(1):54-8. doi: 10.1046/j.1540-8167.2005.04470.x.
• [7] Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev Technol. 2004 Oct;2(5):497-506. doi: 10.1089/adt.2004.2.497.
• [8] Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.
• [9] Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol. 2008 Nov;155(6):957-66. doi: 10.1038/bjp.2008.325. Epub 2008 Aug 25.
• [10] Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy. Br J Pharmacol. 2006 Mar;147(6):642-52. doi: 10.1038/sj.bjp.0706508.
• [11] Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol. 1999 Mar;359(3):212-9. doi: 10.1007/pl00005344.
• [12] Redox state dependency of HERGS631C channel pharmacology: relation to C-type inactivation. FEBS Lett. 2000 May 26;474(1):111-5. doi: 10.1016/s0014-5793(00)01586-6.
• [13] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [14] Ethnic-Related Sodium Voltage-Gated Channel Subunit 5 Polymorphisms Shape the In Vitro Pharmacological Action of Amiodarone upon Na(v)1.5. Mol Pharmacol. 2021 Jun;99(6):448-459. doi: 10.1124/molpharm.120.000176. Epub 2021 Apr 6.
• [15] Flecainide test in Brugada syndrome: a reproducible but risky tool. Pacing Clin Electrophysiol. 2003 Jan;26(1P2):338-41. doi: 10.1046/j.1460-9592.2003.00045.x.
• [16] Inhibitory effects of cannabidiol on voltage-dependent sodium currents. J Biol Chem. 2018 Oct 26;293(43):16546-16558. doi: 10.1074/jbc.RA118.004929. Epub 2018 Sep 14.
• [17] Regulatory effects of non-steroidal anti-inflammatory drugs on cardiac ion channels Nav1.5 and Kv11.1. Chem Biol Interact. 2021 Apr 1;338:109425. doi: 10.1016/j.cbi.2021.109425. Epub 2021 Feb 19.
• [18] Quantitative proteomic analysis of HepG2 cells treated with quercetin suggests IQGAP1 involved in quercetin-induced regulation of cell proliferation and migration. OMICS. 2009 Apr;13(2):93-103. doi: 10.1089/omi.2008.0075.
• [19] Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol. 2013 Oct 1;272(1):245-55.
• [20] Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2016 Apr 1;296:42-53. doi: 10.1016/j.taap.2016.01.015. Epub 2016 Jan 25.
• [21] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [22] Modulation of the heart's electrical properties by the anticonvulsant drug retigabine. Toxicol Appl Pharmacol. 2017 Aug 15;329:309-317. doi: 10.1016/j.taap.2017.06.018. Epub 2017 Jun 20.